Want to see IN:VINEETLAB full AI Analyst Report?
VINEETLAB Stock Chart & Stats
₹40.51
₹2.19(3.77%)
At close: 4:00 PM EST
₹40.51
₹2.19(3.77%)
Day’s Range― - ―
52-Week Range₹27.91 - ₹43.56
Previous CloseN/A
Volume164.54K
Average Volume (3M)30.12K
Market Cap
₹729.84M
Enterprise Value₹788.83
Total Cash (Recent Filing)₹170.75M
Total Debt (Recent Filing)₹453.25M
Price to Earnings (P/E)44.0
Beta0.60
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.85
Shares Outstanding19,206,266
10 Day Avg. Volume30,563
30 Day Avg. Volume30,117
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.71
Price to Sales (P/S)0.54
P/FCF Ratio-1.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Earnings RecoveryThe return to positive earnings and stronger operating margins improves the company’s ability to fund operations and absorb cost pressure. However, the low net margin provides limited cushion, so the recovery must persist to become durable.
Lower LeverageDeleveraging reduces balance-sheet strain and improves financial flexibility compared with the stressed 2025 position. A stronger equity base may help the company support operations and investment, although leverage remains meaningful.
Revenue ReboundThe return to revenue growth indicates renewed demand or improved execution after two difficult years. If maintained, a broader top-line recovery could support operating leverage and strengthen the earnings base, though consistency remains unproven.
Bears Say
Weak Cash ConversionPersistent negative operating and free cash flow indicates that accounting earnings are not reliably converting into liquidity. This can increase reliance on funding, constrain investment, and heighten vulnerability when demand or profitability weakens.
Volatile Revenue HistoryLarge year-to-year revenue swings make planning and capacity utilization more difficult and reduce confidence in the durability of the recovery. Uneven demand can also amplify margin pressure and working-capital volatility across cycles.
Thin ReturnsLow net profitability and return on equity show that the improved balance sheet is not yet generating strong shareholder returns. With leverage still meaningful, limited earnings cushion could leave results sensitive to costs, pricing, or execution.
Vineet Laboratories Ltd. News
VINEETLAB FAQ
What was Vineet Laboratories Ltd.’s price range in the past 12 months?
Vineet Laboratories Ltd. lowest stock price was ₹27.91 and its highest was ₹43.56 in the past 12 months.
What is Vineet Laboratories Ltd.’s market cap?
Vineet Laboratories Ltd.’s market cap is ₹729.84M.
When is Vineet Laboratories Ltd.’s upcoming earnings report date?
Vineet Laboratories Ltd.’s upcoming earnings report date is Nov 06, 2026 which is in 62 days.
How were Vineet Laboratories Ltd.’s earnings last quarter?
Vineet Laboratories Ltd. released its earnings results on Feb 14, 2026. The company reported ₹0.923 earnings per share for the quarter.
Is Vineet Laboratories Ltd. overvalued?
According to Wall Street analysts Vineet Laboratories Ltd.’s price is currently Overvalued.
Does Vineet Laboratories Ltd. pay dividends?
Vineet Laboratories Ltd. pays a Notavailable dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Vineet Laboratories Ltd. dividends here
What is Vineet Laboratories Ltd.’s EPS estimate?
Vineet Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vineet Laboratories Ltd. have?
Vineet Laboratories Ltd. has 19,206,266 shares outstanding.
What happened to Vineet Laboratories Ltd.’s price movement after its last earnings report?
Vineet Laboratories Ltd. reported an EPS of ₹0.923 in its last earnings report. Following the earnings report the stock price went up 2.422%.
Which hedge fund is a major shareholder of Vineet Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:VINEETLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vineet Laboratories Ltd.
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.
Technical Analysis
Diamines & Chemicals Ltd.
―
DMCC Speciality Chemicals Limited
―
Indo Amines Limited
―
Primo Chemicals Limited
―
Ishan Dyes and Chemicals Limited
―